Thailand is strengthening its vaccine safety and accelerating its ambition to turn out to be Southeast Asia’s main biopharmaceutical hub by the National Biopharmaceutical Facility (NBF), a state-backed heart designed to assist analysis, improvement, Good Manufacturing Practice (GMP) manufacturing, and contract improvement and manufacturing group (CDMO) providers.
Ahead of CPHI South East Asia 2026, Thailand welcomed a global media delegation to the National Biopharmaceutical Facility at King Mongkut’s University of Technology Thonburi (KMUTT) in Bangkok, offering a firsthand have a look at the nation’s built-in biopharmaceutical ecosystem—from laboratory analysis and bioprocess improvement to analytical testing, GMP manufacturing, and expertise switch.
The media tour, organized by Informa Markets (Thailand), highlighted Thailand’s rising capabilities in attracting funding, fostering innovation, and increasing biopharmaceutical manufacturing throughout the ASEAN area.
The showcase comes as Southeast Asia’s biopharmaceutical industry is poised for fast enlargement. According to IMARC Group, the regional market, valued at US$6.7 billion in 2025, is projected to just about double to US$12.8 billion by 2034, fueled by rising healthcare spending, ageing populations, growing power illnesses, supportive authorities insurance policies, and advances in biotechnology.
Against this backdrop, Thailand is investing closely in nationwide biopharmaceutical infrastructure to strengthen its competitiveness and set up itself as a regional heart for innovation and superior manufacturing.
National infrastructure for the long run
Located throughout the KMUTT Bangkhuntien Science and Industrial Park—Thailand’s first University Technology Park—the National Biopharmaceutical Facility serves as a strategic nationwide infrastructure supporting the nation’s next-generation life sciences trade.
Backed by greater than US$80 million in investments protecting amenities, tools, and manufacturing infrastructure, the NBF is about to turn out to be Thailand’s first state-owned Contract Development and Manufacturing Organization (CDMO) devoted to creating and producing clinical- and research-grade biopharmaceuticals beneath GMP requirements.
Beyond manufacturing, the power helps expertise switch, manufacturing scale-up, and the localization of superior biopharmaceutical applied sciences, serving to cut back dependence on imported biologics whereas strengthening nationwide vaccine safety and regional manufacturing capability.
“The National Biopharmaceutical Facility is more than a research center,” KMUTT officers stated. “It is a strategic national infrastructure that bridges scientific research with industrial competitiveness and supports the sustainable growth of Thailand’s biopharmaceutical industry.”
Strengthening vaccine safety
During the go to, Dr. Warinthorn Songkasiri, Vice President for Research Strategy at KMUTT and Acting Director of the National Biopharmaceutical Facility, outlined the NBF’s function in enhancing Thailand’s vaccine safety and strengthening the nation’s analysis, improvement, and manufacturing capabilities for biopharmaceutical merchandise.
She stated the power is designed to enhance Thailand’s preparedness for future public well being emergencies whereas creating scientific experience, superior applied sciences, expert professionals, and stronger partnerships amongst authorities companies, universities, hospitals, and personal trade.
The initiative additionally seeks to broaden collaboration throughout ASEAN, supporting regional resilience in vaccine and biologics manufacturing.
Three facilities of excellence
The National Biopharmaceutical Facility integrates three specialised facilities that assist each stage of biopharmaceutical improvement.
The Bioprocess Research and Innovation Center (BRIC) focuses on course of improvement, optimization, manufacturing scale-up, GMP-compliant cell banking, expertise switch, and workforce coaching, serving to researchers and biotechnology corporations translate laboratory discoveries into business manufacturing.
The Biopharmaceutical Characterization Laboratory (BPCL), working beneath ISO/IEC 17025, is acknowledged as ASEAN’s first devoted biopharmaceutical characterization laboratory. It gives analytical testing, product characterization, high quality evaluation, and regulatory assist to satisfy worldwide requirements.
Completing the ecosystem is the GMP Production Facility, which helps pilot-scale manufacturing of medical research-grade biopharmaceutical merchandise utilizing microbial, mammalian cell, and single-use expertise platforms. Its capabilities embody aseptic filling, course of validation, pilot manufacturing, and manufacturing scale-up.
Together, the three amenities present Thailand with an built-in platform protecting analysis, analytical characterization, pilot manufacturing, and business readiness—bridging the hole between scientific discovery and industrial manufacturing.
Officials stated the ecosystem permits universities, biotechnology companies, pharmaceutical producers, and worldwide companions to speed up product improvement, enhance expertise switch, cut back improvement prices, and strengthen Thailand’s place as one in every of ASEAN’s rising biopharmaceutical innovation and manufacturing hubs.